CDC ENTEBBE

60 Degrees Pharmaceuticals and Tufts Medical Center signed a Patent License Agreement to advance tafenoquine for babesiosis treatment and prevention. Tafenoquine is not FDA-approved for babesiosis. The agreement includes joint patent ownership, 60 Degrees' exclusive commercialization rights, Tufts MC's research license, royalties for Tufts MC, and 60 Degrees' commitment to product development.

2024 saw significant medical breakthroughs, including gene therapy restoring hearing in children with hereditary deafness, the first genetically-edited pig kidney transplant into a human, discovery of a cause of lupus, FDA approval of the first new class of schizophrenia drug in over 30 years, and authorization of the first over-the-counter combo flu and COVID test outside of emergency use.

Low-density lipoproteins (LDL) cause atherosclerotic cardiovascular disease, with insights from pathophysiology, genetics, and therapy. Emerging therapies focus on reducing LDL cholesterol and apolipoprotein B. Evaluations of LDL reduction and statin treatment effects are ongoing, with guidelines for acute coronary syndrome and cardiovascular disease prevention emphasizing LDL management. Associations between LDL levels and mortality vary, influenced by inflammation and malnutrition. The lipid paradox, where low LDL is linked to higher mortality in some conditions, is explored. Targeted lipid-lowering therapies and inflammation control are key areas of focus.

Bird flu cases rose to 64 this year, with detections in wastewater and signs of dangerous mutations. Experts warn of potential pandemic risk as the virus spreads among animals and humans, with some cases lacking identified sources of infection.

2024 saw significant drug policy changes, including Kamala Harris's pledge to federally legalize cannabis, and rescheduling of cannabis to Schedule III. Lenacapavir, a new HIV prevention drug, was named breakthrough of the year. Weight loss drugs like Ozempic and Wegovy showed potential for treating addiction and neurodegenerative diseases. Overdose deaths declined nationally for the first time since the 1990s, though racial disparities persist. Psychedelics faced setbacks with FDA not approving MDMA for PTSD and Massachusetts rejecting a ballot measure for home-use of psilocybin. The White House accused Syria's Assad of profiting from Captagon sales, leading to its destruction and potential relocation of manufacturing. 'Pink cocaine' gained popularity, posing risks due to its unknown composition.

3D printing has revolutionized pediatric prosthetics, making them stronger, more personalized, and cost-effective. Limbitless Solutions, founded by UCF engineers, has donated bionic arms to 60 families, advancing technology and improving children's lives. The organization collaborates with partners to create expressive designs, enhancing both functionality and personality.

PrEP, a breakthrough medication since 2012, significantly reduces HIV transmission risk by 99% when taken correctly. Available in daily pills, long-acting injectables, and on-demand forms, it's safe for all, including pregnant individuals. Despite its effectiveness, only 25% of those who could benefit are prescribed it, with racial disparities in uptake. A new biannual injection, lenacapavir, nearing FDA approval, shows near 100% protection in trials. PEP, another HIV prevention method, is for emergency use within 72 hours of exposure.

The Pediatric Clinical Trials Market is projected to grow from US$ 20.1 Billion in 2023 to US$ 33.0 Billion by 2033, with a CAGR of 5.0%. North America led in 2023 with a 39.10% share. Challenges include ethical concerns, limited recruitment, and high costs. Innovations like adaptive trials and digital technologies are enhancing efficiency.

GenomOncology appoints Dr. Jonathan "Jack" Lord, M.D., to its Board of Directors. Dr. Lord, a healthcare innovation leader, brings extensive experience in clinical practice, healthcare administration, and advanced analytics. His appointment aligns with GenomOncology's mission to advance precision medicine in oncology.